Drug Trial Radar · NCT06351020
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
387
Actual
Start
Jun 24, 2024
Primary completion
Nov 10, 2026
Study completion Dec 15, 2026
Sponsor
- Lead sponsor
- LaNova Medicines Zhejiang Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of LM-302 Versus Treatment of Physician's Choice (TPC) in Subjects With locally advanced or metastatic, Claudin (CLDN) 18.2-positive, Gastric or Gastroesophageal Junction Adenocarcinoma who have progressed on or after 2 lines of systemic therapy
Conditions
- Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Interventions
LM-302Drug
LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle
ApatinibDrug
The subjects will receive Apatinib orally,qd
IrinotecanDrug
The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: up to 42 months
- Progression Free Survival (PFS)Time frame: up to 42 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.